At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Sebelipase Alfadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open-Label Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency
In Brief
A Phase 2 clinical trial evaluating Sebelipase Alfa for Lysosomal Acid Lipase Deficiency. Completed, enrolled 31 participants across 19 sites in 15 countries.
Detailed Summary
This study evaluated the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency (LAL-D).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLysosomal Acid Lipase Deficiency
CountriesAustralia, Belgium, Brazil, Canada, Croatia, Denmark, Germany, Italy, Mexico, Netherlands, Russia, Spain, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartJun 2014
Primary CompletionDec 2017
TodayJul 2026
First PostedApr 14, 2014
Enrollment StartJun 24, 2014
Primary CompletionDec 28, 2017
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 12.2 years ago
Interventions
Sebelipase Alfadrug
IV infusion of sebelipase alfa